(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA)...
Stats | |
---|---|
今日成交量 | 4 015.00 |
平均成交量 | 25 287.00 |
市值 | 69.36M |
EPS | $0 ( 2024-03-28 ) |
下一个收益日期 | ( $-1.000 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.35 |
ATR14 | $0.122 (0.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-29 | Cataldi Fabio | Buy | 21 138 | Restricted Stock Unit |
2024-02-29 | Oakes Gregory | Buy | 54 454 | Restricted Stock Unit |
2023-05-30 | Batycky Alka | Buy | 3 600 | Stock Option (right to buy) |
2023-05-30 | Batycky Alka | Buy | 0 | |
2023-05-23 | Mayleben Timothy M | Buy | 18 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
96.61 |
Last 91 transactions |
Buy: 96 412 664 | Sell: 25 476 546 |
Landos Biopharma, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-3.50 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-3.50 |
FY | 2022 |
营收: | $0 |
毛利润: | $-577 000 (0.00 %) |
EPS: | $-9.44 |
FY | 2021 |
营收: | $18.00M |
毛利润: | $18.00M (100.00 %) |
EPS: | $-0.981 |
Financial Reports:
No articles found.
Landos Biopharma, Inc.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。